Keyphrases
Systemic Treatment
100%
Pexidartinib
100%
Tenosynovial Giant Cell Tumor
100%
Treatment Options
40%
Functional Limitations
40%
Selective Inhibition
20%
Range of Motion
20%
Placebo
20%
Adverse Events
20%
Liver
20%
Overproduction
20%
Tumor
20%
Surgical Intervention
20%
Adult Patients
20%
FDA-approved Drugs
20%
Physical Function
20%
CSF-1
20%
Tumor Volume
20%
Treatment Discontinuation
20%
Tumor-associated
20%
Severe Morbidity
20%
Tendon Sheath
20%
Daiichi
20%
CSF1R
20%
Tumor Stiffness
20%
Surgical Treatment Options
20%
Surgical Resection
20%
Treatment Interruption
20%
Non-surgical Treatment
20%
Overall Response Rate
20%
Oral Tyrosine Kinase Inhibitors
20%
Dose Reduction
20%
Bursa
20%
Systemic Therapy
20%
Synovium
20%
Medicine and Dentistry
Pexidartinib
100%
Giant Cell Tumor of Tendon Sheath
100%
Systemic Therapy
100%
Neoplasm
40%
Surgery
40%
Functional Limitation
40%
Colony Stimulating Factor 1
40%
Range of Motion
20%
Adverse Event
20%
Clinician
20%
Receptor
20%
Placebo
20%
Tyrosine-Kinase Inhibitor
20%
Conservative Treatment
20%
Treatment Interruption
20%
Synovial Membrane
20%
Peritenon
20%
Drug Dose Reduction
20%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Treatment
100%
Pexidartinib
100%
Giant Cell Tumor of Tendon Sheath
100%
Neoplasm
40%
Colony Stimulating Factor 1
40%
Receptor
20%
Placebo
20%
Adverse Event
20%
Protein Tyrosine Kinase Inhibitor
20%